Condition: Chronic Myelomonocytic Leukemia · Chronic Myelomonocytic Leukemia (CMML) · Chronic Myelomonocytic Leukemia-1 · Sponsor: Solu Therapeutics, Inc
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.
This description comes directly from the study's public registry record.
Head of Clinical Operations · 01+ (781)-874-1100 · mtimothy@solutherapeutics.com
Always discuss trial participation with your own doctor first.
| Stanford University | Stanford, California, United States | Recruiting |
| Moffitt | Tampa, Florida, United States | Recruiting |
| DFCI | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| OHSU | Portland, Oregon, United States | Recruiting |
| Vanderbilt University | Nashville, Tennessee, United States | Not Yet Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06950034